Welcome to our dedicated page for Enzo Biochem SEC filings (Ticker: ENZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how Enzo Biochem funds breakthrough molecular diagnostics and protects its patent estate means wading through dense SEC documents. Revenue mixes shift between reagent sales and technology licensing, R&D outlays rise and fall with pipeline milestones, and FDA-related 8-Ks can appear without notice—critical data that’s often buried across hundreds of pages.
Stock Titan solves this headache. Our feed captures every Enzo Biochem quarterly earnings report 10-Q filing, proxy statement executive compensation table, and 8-K material event the moment EDGAR releases them, then layers on AI-powered summaries that explain the numbers in plain language. Need Enzo Biochem insider trading Form 4 transactions as they happen? Real-time alerts arrive with context so you instantly see whether executives are buying or selling.
Dive into an annual report 10-K simplified view to find year-over-year R&D spend, royalty income from proprietary probes, and reserves for patent litigation. Compare segment margins side-by-side, export key figures, and answer questions like “What does Enzo Biochem report in its SEC filings?”—all without scrolling through footnotes.
- Enzo Biochem Form 4 insider transactions real-time monitoring
- Understanding Enzo Biochem SEC documents with AI highlights
- Enzo Biochem earnings report filing analysis across quarters
- Full-text search of Enzo Biochem proxy statement executive compensation details
- Enzo Biochem 8-K material events explained for FDA updates and patent rulings
Whether you’re modeling assay revenue or watching licensing trends, our comprehensive, AI-enhanced SEC feed equips you to act quickly and confidently—no jargon, no guesswork, just the insights that move Enzo Biochem’s stock.
Enzo Biochem, Inc. (ENZ) entered into and completed a merger in which Bethpage Merger Sub merged into Enzo, and Enzo became a wholly owned subsidiary of Bethpage Parent.
At the effective time on August 20, 2025, each outstanding share was converted into the right to receive $0.70 in cash per share (subject to withholding). Vested restricted stock units held by directors or vested-but-unsettled RSUs were converted into a cash payment equal to the number of underlying shares multiplied by $0.70. Unvested RSUs and all outstanding options were canceled without consideration. As a result, the reporting persons state they no longer beneficially own any Enzo securities and ceased to own more than 5% of the class.
FAQ
What is the current stock price of Enzo Biochem (ENZ)?
What is the market cap of Enzo Biochem (ENZ)?
